Appraising iniparib, the PARP inhibitor that never was—what must we learn?

  title={Appraising iniparib, the PARP inhibitor that never was—what must we learn?},
  author={Joaqu{\'i}n Mateo and Michael K. Ong and David Shao Peng Tan and Michael A. Gonzalez and Johann Sebastian de Bono},
  journal={Nature Reviews Clinical Oncology},
Several drugs targeting poly(ADP-ribose) polymerase (PARP) enzymes are under development. Responses have been observed in patients with germline mutations in BRCA1 and BRCA2, with further data supporting antitumour activity of PARP inhibitors in sporadic ovarian cancer. Strategies to identify other predictive biomarkers remain under investigation. Iniparib was purported to be a PARP inhibitor that showed promising results in randomized phase II trials in patients with triple-negative breast… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 23 extracted citations


Publications referenced by this paper.
Showing 1-10 of 95 references

Sanofi . Press release : Sanofi provides update on phase 3 studies of two investigational compounds [ online ]

  • C. G. Begley, L. Ellis
  • 2013

phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets) [abstract 515

  • Anders, C. K. et al. TBCRC018
  • J. Clin. Oncol. 31 (Suppl.), a515
  • 2013

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors

  • A Rajan
  • Clin. Cancer Res
  • 2012

A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triplenegative breast cancer (TNBC) [abstract

  • Llombart, A. et al. SOLTI NeoPARP
  • J. Clin. Oncol. 30 (Suppl.), a1011
  • 2012

Comparative effetiveness of olaparib and iniparib [abstract

  • Cotter, M. B. et al. Preclinical evaluation of PARP inhibitio cancer
  • J. Clin. Oncol. 30 (Suppl.), a1042
  • 2012

Similar Papers

Loading similar papers…